Abstract

Rituximab resulted in an overall platelet count response in 62.5% of adults with ITP. However, this finding derives from uncontrolled studies that also reported significant toxicities, including death in 2.9% of cases. These data suggest that providers should avoid indiscriminate use of rituximab and that randomized, controlled trials of rituximab for ITP are urgently needed.

Keywords

MedicineRituximabThrombocytopenic purpuraInternal medicineClinical trialSplenectomyAdverse effectCochrane LibraryHematologyPlateletMeta-analysisLymphoma

Affiliated Institutions

Related Publications

Publication Info

Year
2007
Type
review
Volume
146
Issue
1
Pages
25-33
Citations
548
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

548
OpenAlex

Cite This

Donald M. Arnold, Francesco Dentali, Mark Crowther et al. (2007). Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura. Annals of Internal Medicine , 146 (1) , 25-33. https://doi.org/10.7326/0003-4819-146-1-200701020-00006

Identifiers

DOI
10.7326/0003-4819-146-1-200701020-00006